Flavio Vincenti
Internal Medicine · San Francisco, CANPI 1790732543
Payments from drug & device makers
Across 642 payments — averaging $4452.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$796K
- Regeneron$600K
- Amgen$469K
- Sanofi US Services Inc.$377K
- CSL Behring$185K
- E.r. Squibb & Sons, L.L.C.$78K
- plus $353K from 13 others
Across 3 payments — averaging $1030.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Pharma AG$2K
- Pfizer$940
What the payments were for
- Consulting fees$107,09959%
- Speaking & faculty fees$20,55311%
- Travel & lodging$49,33727%
- Food & beverage$2,1411%
- Education$3,5252%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 266 | $795,787 |
| Regeneron | 128 | $600,287 |
| Amgen(2 entities) | 7 | $469,230 |
| Sanofi US Services Inc. | 16 | $376,586 |
| CSL Behring | 136 | $185,141 |
| E.r. Squibb & Sons, L.L.C. | 16 | $78,223 |
| Novartis | 7 | $66,012 |
| Genentech, Inc. | 3 | $57,970 |
| Boehringer Ingelheim | 5 | $54,022 |
| Pfizer | 11 | $50,492 |
| Alnylam Pharmaceuticals Inc. | 5 | $33,394 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $26,381 |
| AstraZeneca | 13 | $22,981 |
| Sanofi-aventis U.S. LLC | 2 | $12,527 |
| Sanofi | 7 | $9,802 |
| Mallinckrodt Hospital Products Inc. | 5 | $8,823 |
| Veloxis Pharmaceuticals, Inc. | 4 | $7,775 |
| Calliditas Therapeutics US Inc. | 1 | $2,155 |
| Boehringer Ingelheim International GmbH | 2 | $926 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GAMMAGARD LIQUID$25,149
- PREVYMIS$23,583
- THYMOGLOBULIN$9,592
- Envarsus$7,909
- UVADEX$6,750
- ULTOMIRIS$6,601
- NULOJIX$3,525
- TARPEYO$2,155
- CELLEX$2,073
- KRYSTEXXA$104
How this compares
$2,858,513 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Francisco
- Rahul AggarwalSan Francisco$24M
- Thomas MartinSan Francisco$13.7M
- Peter HuntSan Francisco$9.8M
- Diane HavlirSan Francisco$8.4M
- Sandy WongSan Francisco$6.6M
- Nina ShahSan Francisco$5.4M
- Katy TsaiSan Francisco$3.8M
- Riley BoveSan Francisco$3.6M
- Jacob LalezariSan Francisco$3.3M
- John FahySan Francisco$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.